



ACTIVITY DISCLOSURE STATEMENT

**Stem Cell Medicine: From Scientific Research to Patient Care
736197-2502**

Date of Original Release: May 2, 2025 / Termination Date: May 1, 2028

Accreditation

In support of improving patient care, this activity has been planned and implemented by Harvard Medical School and the International Society for Stem Cell Research. Harvard Medical School is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Accreditation

The Harvard Medical School designates this enduring material activity for a maximum of 2.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Accreditation

Harvard Medical School designates this enduring material for a maximum of 2.25 ANCC contact hours.

All individuals in a position to control the content of this activity have been asked to disclose any relationship they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The following planners, speakers, and content reviewers have reported relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated:

NAME	COMPANY	RELATIONSHIP
<u>Course Planners:</u>		
Denise de Villa, JD, RN	Merck	Employee/Ownership Interest (ended November 2022)
	Citius Pharmaceuticals	Stock (Publicly Held)
	Ginkgo Bioworks	Stock (Publicly Held)
	Bristol-Myers Squibb	Stock (Publicly Held)
	Moderna	Stock (Publicly Held)
Jaime Imitola, MD	Genentech	Research Support
	Biogen	Research Support
	Novartis	Consultant
<u>Course Faculty:</u>		
Roger Barker, MBBS, MRCP PhD	Novo Nordisk	Consultant
	Bayer/BlueRock	Consultant
	UCB	Consultant
	Treefrog	Consultant
	Harness Therapeutics	Consultant
Insoo Hyun, PhD	Bayer	Consultant
Hideyuki Okano, MD, PhD	Eisai Co	Advisory Board/Committee

	SanBio Company Limited	Advisory Board/Committee
	K Pharma	Advisory Board/Committee, Stock (Publicly Held)
Graziella Pellegrini, PhD	Holostem Terapie Avanzate	Board of Trustees

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACTIVITY COMMERCIAL SUPPORT

This activity is supported by educational grants from Bayer, Blue Rock, NovoNordisk, and Vertex.